Imugene Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Imugene hat ein Gesamteigenkapital von A$194.8M und eine Gesamtverschuldung von A$0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen A$230.4M bzw. A$35.6M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

AU$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	AU$139.39m
Eigenkapital	AU$194.83m
Gesamtverbindlichkeiten	AU$35.59m
Gesamtvermögen	AU$230.42m

Jüngste Berichte zur Finanzlage

Recent updates

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Apr 12

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Sep 19

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

May 30

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Jan 30

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: IMUDie kurzfristigen Aktiva des Unternehmens (A$167.7M) übersteigen seine kurzfristigen Passiva (A$29.3M).

Langfristige Verbindlichkeiten: IMUDie kurzfristigen Vermögenswerte des Unternehmens (A$167.7M) übersteigen seine langfristigen Verbindlichkeiten (A$6.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: IMU ist schuldenfrei.

Schulden abbauen: IMU hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: IMU auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: IMU verfügt über eine ausreichende Liquiditätsreserve für 2 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 40.6% pro Jahr abnimmt.

Imugene Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Recent updates

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Imugene Limited, Annual General Meeting, Nov 30, 2023

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Less than half of directors are independent

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Price target decreased by 14% to AU$0.42

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Price target decreased by 9.8% to AU$0.46

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Price target decreased to AU$0.52

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Independent Non-Executive Director exercised options to buy AU$3.2m worth of stock.

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Price target decreased to AU$0.51

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Consensus forecasts updated

Price target decreased to AU$0.52

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$1.5m worth of stock.

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Consensus forecasts updated

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock

Imugene Limited Provides Phase 1 Clinical Trial Update of Its Immunotherapy Pd1-Vaxx

Imugene Presents HER-Vaxx Update at ESMO World GI Congress

Imugene Limited Announces FDA IND Approval of New Oncolytic Virotherapy Checkvacc Virotherapy Checkvacc

CEO, MD & Executive Director exercised options and sold AU$1.6m worth of stock

Independent Non-Executive Director recently sold AU$1.2m worth of stock

Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 0.324115 million.

Revenue and earnings in line with expectations

A Look At Imugene's (ASX:IMU) CEO Remuneration